Advertisement

Eptifibatide Injection

[11 August 2016]

Products Affected - Description

All presentations are currently available

Reason for the Shortage

  • Merck states the reason for the shortage was manufacturing delay.
  • AuroMedics launched eptifibatide injection in December 2015.

Available Products

Integrilin injection, Merck
0.75 mg/mL, 100 mL vial, 1 count (NDC 00085-1136-01)
2 mg/mL, 10 mL vial, 1 count (NDC 00085-1177-01)
2 mg/mL, 100 mL vial, 1 count (NDC 00085-1177-02)
 
Eptifibatide injection, AuroMedics
0.75 mg/mL, 100 mL vial, 1 count (NDC 55150-0218-99)
2 mg/mL, 10 mL vial, 1 count (NDC 55150-0219-10)
2 mg/mL, 100 mL vial, 1 count (NDC 55150-0220-99)

Estimated Resupply Dates

All marketed presentations are available.

Related Shortages

Updated

August 11, July 21, May 16, April 6, March 15, February 4, January 28, 2016; December 29, 22 and 1, October 28 and 8, September 23, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing